Glucose Monitoring Global Market - Forecast to 2029
Glucose Monitoring Global Market - Forecast to 2029
Abstract
Glucose Monitoring consists of products that are essential for measuring glucose levels in diabetes patients. With the projected rise in the aged population and awareness about diabetes conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the glucose monitoring global market is expected to grow at a double digit CAGR from 2022 to 2029 reach $33,886.4 million by 2029.
Factors driving the Glucose Monitoring market are the global rise in the prevalence of diabetes, increasing demand for a less minimally invasive or non-invasive and point-of-care device; increasing R&D investments are driving the market growth, whereas, the growing diffusion of smart devices and digital platforms increasing compliance and management of diabetes is creating opportunities in the coming years. The high cost of the products, frequent product recalls and inadequate reimbursement is restraining the market growth. The stringent regulations for product approval, privacy concerns and safety issues are threats for the market growth.
Glucose Monitoring global market is segmented based on products, sample source, end-users and geography. The products market is divided into three segments, namely, Invasive, non-Invasive and lab-based glucose monitoring products. Among them, the Invasive glucose monitoring products segment accounted for the largest share in 2022 and is projected to grow at a double digit CAGR from 2022 to 2029 due to technological advancements, easy use, and patient-friendly nature of products. The non-invasive glucose monitoring segment is projected to grow at mid single digit CAGR from 2022 to 2029. The lab-based glucose monitoring segment contributed about XX% of the revenue and is projected to grow at low single digit CAGR from 2022 to 2029.
The Invasive glucose monitoring products are further segmented into self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) products, among them, the continuous glucose monitoring segment accounted for the largest share in 2022 and is expected to grow at high teen CAGR from 2022 to 2029 due to increasing awareness among patients and introduction of connected devices for integrated health management. The continuous glucose monitoring market is further sub-segmented into sensors and receivers & transmitters, among which, the sensors segment is the fastest-growing segment and is projected to grow at high single CAGR from 2022 to 2029.The Self glucose monitoring products are further sub-segmented into blood glucose monitors, blood glucose test strips, and lancets & others. The blood glucose testing strips segment accounted for the largest share in 2022 due development of no coding strips. Lancets and others contributed XX% revenue while the glucose meters contributed remaining XX% revenue in 2022.
Based on sample source the market is segmented into blood, urine and others. The blood segment accounted for the largest share in 2022 and is projected to grow at double digit CAGR from 2022 to 2029 due to the high accuracy of results. Other source-based glucose monitoring segment is the fastest-growing segment and is projected to grow at a strong double digit CAGR from 2022 to 2029 due to increased R&D investment, many products getting regulatory approved and ready to launch products.
Based on end-users the market is segmented into hospitals, private clinics, home care and ambulatory settings, among them, the home care segment accounted for the largest share in 2022 and is projected to grow at early teen CAGR from 2022 to 2029 due to the availability of over the counter (OTC) self blood glucose monitor and ease in operating these monitors and thereby reducing the frequent visits to hospitals or clinics for checking glucose levels. The hospitals segmented contributed XX% revenue in 2022 and is projected to grow at double digit CAGR from 2022 to 2029, the ambulatory settings contributed about XX% revenue in 2022 and is projected to grow at double digit CAGR from 2022 to 2029 and the private clinics segment contributed the remaining XX% revenue and is projected to grow at high single digit CAGR from 2022 to 2029.
Based on geography the market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of E.U.), Asia-Pacific (Japan, China, India and Rest of APAC) and the Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the largest market share in 2022 and the market is projected to grow at double digit CAGR from 2022 to 2029. The European market is the fastest growing region with early teen CAGR from 2022 to 2029 due to a steep rise in the aging population, advancement in technology, awareness of people about treatment options and favorable government policies. The Asia-Pacific market is projected to grow at double digit CAGR from 2022 to 2029, while the RoW region is projected to grow at high single digit CAGR from 2022 to 2029.
Major players in the Glucose monitoring market include Abbott Laboratories (U.S.), Dexcom (U.S.), Roche (Switzerland), LifeScan (U.S.), Medtronic, Inc. (Ireland), PHC Holding (Ascensia) (Japan), Sinocare (China), Arkray (Japan), Bio-Rad Laboratories (U.S.), and i-Sens, Inc., (South Korea), etc.
Content
Table of Contents
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 THE GLOBAL RISE IN THE PREVALENCE OF DIABETES
3.3.1.2 INCREASING DEMAND FOR MINIMALLY OR NON-INVASIVE AND POINT-OF-CARE DEVICES.
3.3.1.3 INCREASING R & D INVESTMENTS
3.3.1.4 GROWING DIFFUSION OF SMART DEVICES AND DIGITAL PLATFORMS INCREASING COMPLIANCE AND MANAGEMENT OF DIABETES
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 HIGH COST ASSOCIATED WITH THE PRODUCTS
3.3.2.2 INADEQUATE REIMBURSEMENT
3.3.2.3 PRODUCT RECALLS
3.3.2.4 STRICT REGULATION OF GLUCOSE MONITORING DEVICES BY REGULATORY ORGANIZATIONS LIKE THE FDA AND OTHERS
3.3.2.5 PRIVACY CONCERN AND SAFETY ISSUES IN CONNECTED DEVICES
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 INDIA
3.4.5 JAPAN
3.5 REIMBURSEMENT SCENARIO
3.6 PATENT ANALYSIS
3.7 TECHNOLOGY ADVANCEMENTS
3.7.1 NON-INVASIVE GLUCOSE MONITORING TECHNOLOGIES
3.7.1.1 OPTICAL GLUCOSE MONITORING
3.7.1.2 BREATH GLUCOSE MONITORING
3.7.1.3 SWEAT GLUCOSE MONITORING
3.7.1.4 PIPELINE OF NON-INVASIVE GLUCOSE MONITORING DEVICES
3.8 FUNDING SCENARIO
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 BARGAINING POWER OF SUPPLIERS
3.9.4 BARGAINING POWER OF BUYERS
3.9.5 RIVALRY AMONG EXISTING COMPETITORS
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10.1 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.10.2 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.10.3 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.11 REGIONAL MARKET SHARE ANALYSIS
3.11.1 NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALSIS
3.11.2 EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.3 ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.4 ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.5 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.6 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.7 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.8 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12 UNITS SOLD
3.12.1 GLUCOSE TESTING STRIPS UNITS SOLD
3.12.2 NUMBER OF CGM SENSORS SOLD
3.13 MARKET PENETRATION ANALYSIS
3.13.1 GLOBAL SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.2 NORTH AMERICA SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.2.1 U.S. SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.2.2 REST OF N.A. SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3 EUROPE SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.1 GERMANY SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.2 FRANCE SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.3 ITALY SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.4 REST OF E.U. SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4 ASIA-PACIFIC SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.1 JAPAN SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.2 CHINA SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.3 INDIA SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.4 REST OF APAC SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5 REST OF THE WORLD SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5.1 BRAZIL SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5.2 MIDDLE EAST & OTHERS SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5.3 REST OF LATAM SMBG AND CGM MARKET PENETRATION ANALYSIS
4 GLUCOSE MONITORING GLOBAL MARKET, BASED ON PRODUCTS
4.1 INTRODUCTION
4.2 INVASIVE GLUCOSE MONITORING
4.2.1 SELF GLUCOSE MONITORING
4.2.1.1 BLOOD GLUCOSE METER
4.2.1.2 BLOOD GLUCOSE TESTING STRIPS
4.2.1.3 LANCETS & OTHERS
4.2.2 CONTINUOUS GLUCOSE MONITORING
4.2.2.1 GLUCOSE SENSORS
4.2.2.2 TRANSMITTERS AND RECEIVERS
4.3 NON-INVASIVE GLUCOSE MONITORING
4.4 LAB BASED GLUCOSE MONITORING
5 GLUCOSE MONITORING GLOBAL MARKET, BASED ON SAMPLE SOURCE
5.1 INTRODUCTION
5.2 BLOOD-BASED GLUCOSE MONITORING
5.3 URINE BASED GLUCOSE MONITORING
5.4 OTHER SOURCES BASED GLUCOSE MONITORING
6 GLUCOSE MONITORING GLOBAL MARKET, BASED ON END-USERS
6.1 INTRODUCTION
6.2 HOSPITALS
6.3 HOME CARE
6.4 PRIVATE CLINICS
6.5 AMBULATORY SETTINGS
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 ITALY
7.3.3 FRANCE
7.3.4 REST OF EUROPE
7.4 ASIA - PACIFIC
7.4.1 JAPAN
7.4.2 CHINA
7.4.3 INDIA
7.4.4 REST OF ASIA-PACIFIC
7.5 REST OF THE WORLD
7.5.1 BRAZIL
7.5.2 MIDDLE EAST & OTHERS
7.5.3 REST OF LATIN AMERICA
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 AGREEMENTS, COLLABORATION & PARTNERSHIPS
8.3 APPROVALS
8.4 NEW PRODUCT LAUNCH
8.5 OTHER DEVELOPMENTS
9 MAJOR COMPANIES
9.1 ABBOTT LABORATORIES, INC.
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 ARKRAY, INC.
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 BIO-RAD LABORATORIES, INC.
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 DEXCOM, INC.
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 I-SENS, INC.
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 LIFESCAN
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 MEDTRONIC, PLC
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 PHC HOLDINGS (ASCENCIA DIABETES)
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 ROCHE HOLDINGS AG
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 SINOCARE INC.
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 2 SELF-MONITORING GLUCOSE TESTING STRIPS GLOBAL UNITS SOLD, BASED ON REGION, (2021-2029) (MN)
TABLE 3 CGM SENSORS GLOBAL UNITS SOLD, BASED ON REGION, (2021-2029) (MN)
TABLE 4 GLUCOSE MONITORING DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 5 INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 6 INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 7 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 8 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 9 BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 10 BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 11 LANCETS & OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 12 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 13 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 14 GLUCOSE SENSORS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 15 TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 16 NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 17 LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 18 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED SAMPLE SOURCE, (2021-2029) ($MN)
TABLE 19 BLOOD-BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 20 URINE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 21 OTHER SOURCES BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 22 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON END-USER, (2021-2029) ($MN)
TABLE 23 HOSPITAL GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 24 HOME CARE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 25 PRIVATE CLINICS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 26 AMBULATORY SETTING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 27 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 28 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 29 NORTH AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 30 NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 31 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 32 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 33 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 34 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 35 U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 36 REST OF N. A. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 37 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 38 EUROPE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 39 EUROPE SELF BLOOD GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 40 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 41 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 42 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 43 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 44 GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 45 ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 46 FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 47 REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 48 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 49 ASIA-PACIFIC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 50 ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 51 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 52 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 53 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 54 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 55 JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 56 CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 57 INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 58 REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 59 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 60 ROW INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 61 ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 62 ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 63 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 64 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 65 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 66 BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 67 MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 68 REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 69 AGREEMENTS, COLLABORATION & PARTNERSHIPS (2021-2023)
TABLE 70 APPROVALS (2021-2023)
TABLE 71 NEW PRODUCT LAUNCH (2021-2023)
TABLE 72 OTHERS (2021-2023)
TABLE 73 ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 74 ABBOTT LABORATORIES, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
TABLE 75 ABBOTT LABORATORIES, INC: TOTAL REVENUE OF MEDICAL DEVICES, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
TABLE 76 ABBOTT LABORATORIES, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
TABLE 77 BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
TABLE 78 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2020-2022) ($MN)
TABLE 79 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) ($MN)
TABLE 80 DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
TABLE 81 DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) ($MN)
TABLE 82 I-SENS, INC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
TABLE 83 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 84 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 85 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 86 PHC HOLDINGS: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 87 PHC HOLDINGS: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 88 PHC HOLDINGS: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 89 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 90 ROCHE HOLDINGS AG: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
TABLE 91 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE, BASED ON SUB-SEGMENT, (2020-2022) ($MN)
TABLE 92 ROCHE HOLDINGS AG: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
TABLE 93 SINOCARE, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
LIST OF FIGURES
FIGURE 1 GLUCOSE MONITORING GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION (2021-2029) ($MN) (%)
FIGURE 2 RESEARCH METHODOLOGY: GLUCOSE MONITORING GLOBAL MARKET
FIGURE 3 GLUCOSE MONITORING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 GLUCOSE MONITORING GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 GLUCOSE MONITORING GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION
FIGURE 7 PRODUCT MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 GLUCOSE MONITORING GLOBAL MARKET: PATENT FILING, BASED ON MAJOR PLAYERS (2017-2022)
FIGURE 10 GLUCOSE MONITORING MARKET: PORTER’S ANALYSIS
FIGURE 11 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 12 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 13 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 14 NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 15 EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 16 ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 17 ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 18 NORTH AMERICA CONTINOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 19 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 20 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 21 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 22 SELF MONITORING GLUCOSE TEST STRIPS GLOBAL UNITS SOLD, BASED ON REGION AND COUNTRYWISE (2022) (MN)
FIGURE 23 CGM SENSORS GLOBAL UNITS SOLD, BASED ON REGION AND COUNTRYWISE (2022) (MN)
FIGURE 24 GLOBAL SELF-MONITORING OF BLOOD GLUCOSE (SMBG) MARKET PENETRATION, (2022)
FIGURE 25 GLOBAL CONTINUOUS GLUCOSE MONITORING (CGM) MARKET PENETRATION, (2022)
FIGURE 26 NORTH AMERICA SMBG MARKET PENETRATION, (2022)
FIGURE 27 NORTH AMERICA CGM MARKET PENETRATION, (2022)
FIGURE 28 U.S. SMBG MARKET PENETRATION, (2022)
FIGURE 29 U.S. CGM MARKET PENETRATION, (2022)
FIGURE 30 REST OF N.A. SMBG MARKET PENETRATION, (2022)
FIGURE 31 REST OF NA. CGM MARKET PENETRATION, (2022)
FIGURE 32 EUROPE SMBG MARKET PENETRATION, (2022)
FIGURE 33 EUROPE CGM MARKET PENETRATION, (2022)
FIGURE 34 GERMANY SMBG MARKET PENETRATION, (2022)
FIGURE 35 GERMANY CGM MARKET PENETRATION, (2022)
FIGURE 36 FRANCE SMBG MARKET PENETRATION, (2022)
FIGURE 37 FRANCE CGM MARKET PENETRATION, (2022)
FIGURE 38 ITALY SMBG MARKET PENETRATION, (2022)
FIGURE 39 ITALY CGM MARKET PENETRATION, (2022)
FIGURE 40 REST OF E.U. SMBG MARKET PENETRATION, (2022)
FIGURE 41 REST OF E.U. CGM MARKET PENETRATION, (2022)
FIGURE 42 ASIA-PACIFIC SMBG MARKET PENETRATION, (2022)
FIGURE 43 ASIA-PACIFIC CGM MARKET PENETRATION, (2022)
FIGURE 44 JAPAN SMBG MARKET PENETRATION, (2022)
FIGURE 45 JAPAN CGM MARKET PENETRATION, (2022)
FIGURE 46 CHINA SMBG MARKET PENETRATION, (2022)
FIGURE 47 CHINA CGM MARKET PENETRATION, (2022)
FIGURE 48 INDIA SMBG MARKET PENETRATION, (2022)
FIGURE 49 INDIA CGM MARKET PENETRATION, (2022)
FIGURE 50 REST OF APAC SMBG MARKET PENETRATION, (2022)
FIGURE 51 REST OF APAC CGM MARKET PENETRATION, (2022)
FIGURE 52 REST OF THE WORLD SMBG MARKET PENETRATION, (2022)
FIGURE 53 REST OF THE WORLD CGM MARKET PENETRATION, (2022)
FIGURE 54 BRAZIL SMBG MARKET PENETRATION, (2022)
FIGURE 55 BRAZIL CGM MARKET PENETRATION, (2022)
FIGURE 56 MIDDLE EAST & OTHERS SMBG MARKET PENETRATION, (2022)
FIGURE 57 MIDDLE EAST & OTHERS CGM MARKET PENETRATION, (2022)
FIGURE 58 REST OF LATAM SMBG MARKET PENETRATION, (2022)
FIGURE 59 REST OF LATAM CGM MARKET PENETRATION, (2022)
FIGURE 60 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 61 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 62 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 63 NON-INVASIVE GLUCOSE MONITORS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 64 LAB BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 65 GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 66 URINE BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 67 GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 68 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
FIGURE 69 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 70 NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 71 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 72 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 73 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 74 U.S. GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS SAMPLE SOURCE & END-USER (2022 VS 2029)($MN)
FIGURE 75 U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 76 REST OF NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCT, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
FIGURE 77 REST OF N. A. INVASIVEGLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 78 EUROPE AND INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 79 EUROPE SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 80 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 81 EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 82 EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 83 EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 84 GERMANY GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE & END-USER (2022 VS 2029) ($MN)
FIGURE 85 GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 86 ITALY GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS SAMPLE SOURCE & END-USER (2022 VS 2029) ($MN)
FIGURE 87 ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 88 FRANCE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
FIGURE 89 FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 90 REST OF EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
FIGURE 91 REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 92 ASIA-PACIFIC & INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 93 ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 94 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 95 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 96 ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 97 ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 98 JAPAN GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 99 JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 100 CHINA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 101 CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 102 INDIA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 103 INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 104 REST OF APAC GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 105 REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 106 ROW INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 107 ROW SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 108 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 109 ROW GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 110 ROW GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 111 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2022 VS 2029) ($MN)
FIGURE 112 BRAZIL GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 113 BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 114 MIDDLE EAST & OTHERS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 115 MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 116 REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 117 REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 118 KEY GROWTH STRATEGIES (2021–2023)
FIGURE 119 SWOT: ABBOTT LABORATORIES
FIGURE 120 SWOT: ARKRAY, INC
FIGURE 121 SWOT: BIO-RAD LABORATORIES
FIGURE 122 SWOT: DEXCOM INC.
FIGURE 123 SWOT: I-SENS, INC.
FIGURE 124 SWOT: LIFESCAN
FIGURE 125 SWOT: MEDTRONIC, PLC
FIGURE 126 SWOT: PHC HOLDINGS (ASCENSIA DIABETES CARE)
FIGURE 127 SWOT: ROCHE HOLDINGS AG
FIGURE 128 SWOT: SINOCARE
LIST OF COMPANIES MENTIONED IN THE REPORT
1 77 Elektronika KFT
2 A&T Corporation
3 Abbott Laboratories
4 Abronn fze
5 ACON Laboratories, Inc
6 Adaltis S.r.l
7 Agamatrix, Inc.
8 Ailex Technology Group Co., Ltd
9 Alliance International Co. Ltd
10 Allmedicus Co., Ltd
11 Andesfit System Limited
12 Andon Health Co., Ltd.
13 Apex Biotechnology Corp.
14 Arkray, Inc.
15 Ascensia Diabetes Care Holdings AG
16 AYSET Medical Products
17 B. Braun Melsungen AG
18 Beato Curv
19 Becton Dickinson and Company
20 Beijing Dnurse Technology Co.,Ltd
21 Beijing Yicheng Bioelectronics Technology Co., Ltd.
22 Beurer Gmbh
23 BioCARE Corporation
24 Biochemical Systems International S.p.A.
25 Bioland Technology Ltd.
26 Bionime Corporation (GE)
27 Bioptik Ltd.
28 Bio-Rad Laboratories, Inc
29 BioTelemetry (Philips)
30 Biotest Medical Corporation
31 Bremed Limited
32 Cambridge Sensors Ltd (Microdot)
33 CEI Technology, Inc
34 ChungDo Pharm. Co., Ltd.
35 Cnoga Medical
36 Contec Medical Systems Co., Ltd.
37 Convergent Technologies GmbH & Co. KG
38 CTK Biotech, Inc.
39 Danaher Corporation (Hemocue)
40 Dario Health Corp.
41 Delbio, Inc.
42 Dexcom, Inc
43 Diabetomics, Inc
44 Diagnosis S.A.
45 Dialab GmbH
46 DiaMonTech AG
47 Dr. Morepen
48 Drive DeVilbiss Healthcare
49 EasyMax Diabetes Care
50 EKF Diagnostics
51 e-LinkCare Meditech Co., Ltd.
52 Eps Bio Technology Corp.
53 Eser Healthcare Digital Technology Co., Ltd.
54 Fia Biomed Gmbh
55 Fora Care, Inc
56 General Life Biotechnology Co., Ltd.
57 Genesis Health Technologies, Inc.
58 GlucoMe
59 GlucoRx
60 Glysens Incorporated
61 Goldsite Diagnostics Inc.
62 Guilin Urit Electronic Group Co.,Ltd
63 Haiden Technology Pvt Ltd
64 Hangzhou Sejoy Electronics & Instruments Co., Ltd.
65 Hannox International
66 HMD Biomedical Inc.
67 Hubdic Co Ltd
68 Ihealth Labs, Inc.
69 Ime-Dc Gmbh
70 In4 Technology Corporation
71 Informed Data Systems, Inc. (One Drop)
72 Infinovo Medical Co., Ltd.
73 Intuity Medical, Inc.
74 i-Sens
75 Ixensor Company Ltd.
76 Jiangsu Yuyue Medical Equipment & Supply Co., Ltd (Yuwell)
77 Keto-Mojo Europe B.V.
78 K-Jump Health Co., Ltd.
79 Lepu Medical Technology
80 Life Scan, Inc.
81 Lifotronic Technology Co., Ltd
82 Links Medical Products Inc.
83 Lobeck Medical AG
84 L-Tac MediCare Pte Ltd.
85 Medconn Diagnostics
86 Medisana, GmbH
87 Mediwise (V.S. International)
88 Medsource Ozone Biomedicals Pvt. Ltd.
89 Medtronic, PLC
90 Medtrum Technologies, Inc
91 Menarini Group (A. Menarini Diagnostics s.r.l)
92 Mericonn Technology Co., Ltd.
93 Meril Life Sciences Pvt. Ltd.
94 MHC Medical Products, LLC
95 Microlife AG
96 MicroTech Medical, Inc. (Aidex, Ltd)
97 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
98 National Diagnostic Products Pty Ltd (Betachek)
99 Nemaura Medical,Inc.
100 Nipro Corporation
101 Nova Biomedical
102 Noviosense BV
103 nu-beca & maxcellent Co.
104 Occuity
105 Ok Biotech Co., Ltd
106 Omron Healthcare
107 Osang HealthCare Co Ltd
108 Palmdoc, Ltd
109 Paramedical srl
110 Pharma Tech Solutions, Inc.
111 Philosys Co., Ltd.
112 Pkvitality
113 Prodigy Diabetes Care, LLC
114 Pulsatom Healthcare Pvt., Ltd.
115 Roche Diagnostics
116 Romed Holland (Van Oostveen Medical B.V.)
117 Sanofi Diabetes
118 SD Biosensor. Inc.
119 Sensa Core Medical Instrumentation Pvt. Ltd.
120 Senseonics, Inc.
121 Shanghai Umitai Medical Technology Co., Ltd
122 Sinocare Inc
123 Taidoc Technology Corporation
124 Terumo
125 Tianjin Empecs Medical Device Co., Ltd.
126 Trinity Biotech, PLC
127 Trividia Health, Inc.,
128 Tyson Bioresearch Inc
129 Visgeneer
130 VivaChek Biotech (Hangzhou) Co., Ltd
131 Volta S.r.l.
132 WaveForm Technologies, Inc.
133 Wellan Tech Co., Limited
134 Wockhardt Ltd
135 Wuhan J.H.Bio-Tech
136 Wuxi BioHermes Bio & Medical Technology Co. Ltd.
137 Ypsomed AG
Glucose Monitoring consists of products that are essential for measuring glucose levels in diabetes patients. With the projected rise in the aged population and awareness about diabetes conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the glucose monitoring global market is expected to grow at a double digit CAGR from 2022 to 2029 reach $33,886.4 million by 2029.
Factors driving the Glucose Monitoring market are the global rise in the prevalence of diabetes, increasing demand for a less minimally invasive or non-invasive and point-of-care device; increasing R&D investments are driving the market growth, whereas, the growing diffusion of smart devices and digital platforms increasing compliance and management of diabetes is creating opportunities in the coming years. The high cost of the products, frequent product recalls and inadequate reimbursement is restraining the market growth. The stringent regulations for product approval, privacy concerns and safety issues are threats for the market growth.
Glucose Monitoring global market is segmented based on products, sample source, end-users and geography. The products market is divided into three segments, namely, Invasive, non-Invasive and lab-based glucose monitoring products. Among them, the Invasive glucose monitoring products segment accounted for the largest share in 2022 and is projected to grow at a double digit CAGR from 2022 to 2029 due to technological advancements, easy use, and patient-friendly nature of products. The non-invasive glucose monitoring segment is projected to grow at mid single digit CAGR from 2022 to 2029. The lab-based glucose monitoring segment contributed about XX% of the revenue and is projected to grow at low single digit CAGR from 2022 to 2029.
The Invasive glucose monitoring products are further segmented into self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) products, among them, the continuous glucose monitoring segment accounted for the largest share in 2022 and is expected to grow at high teen CAGR from 2022 to 2029 due to increasing awareness among patients and introduction of connected devices for integrated health management. The continuous glucose monitoring market is further sub-segmented into sensors and receivers & transmitters, among which, the sensors segment is the fastest-growing segment and is projected to grow at high single CAGR from 2022 to 2029.The Self glucose monitoring products are further sub-segmented into blood glucose monitors, blood glucose test strips, and lancets & others. The blood glucose testing strips segment accounted for the largest share in 2022 due development of no coding strips. Lancets and others contributed XX% revenue while the glucose meters contributed remaining XX% revenue in 2022.
Based on sample source the market is segmented into blood, urine and others. The blood segment accounted for the largest share in 2022 and is projected to grow at double digit CAGR from 2022 to 2029 due to the high accuracy of results. Other source-based glucose monitoring segment is the fastest-growing segment and is projected to grow at a strong double digit CAGR from 2022 to 2029 due to increased R&D investment, many products getting regulatory approved and ready to launch products.
Based on end-users the market is segmented into hospitals, private clinics, home care and ambulatory settings, among them, the home care segment accounted for the largest share in 2022 and is projected to grow at early teen CAGR from 2022 to 2029 due to the availability of over the counter (OTC) self blood glucose monitor and ease in operating these monitors and thereby reducing the frequent visits to hospitals or clinics for checking glucose levels. The hospitals segmented contributed XX% revenue in 2022 and is projected to grow at double digit CAGR from 2022 to 2029, the ambulatory settings contributed about XX% revenue in 2022 and is projected to grow at double digit CAGR from 2022 to 2029 and the private clinics segment contributed the remaining XX% revenue and is projected to grow at high single digit CAGR from 2022 to 2029.
Based on geography the market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of E.U.), Asia-Pacific (Japan, China, India and Rest of APAC) and the Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the largest market share in 2022 and the market is projected to grow at double digit CAGR from 2022 to 2029. The European market is the fastest growing region with early teen CAGR from 2022 to 2029 due to a steep rise in the aging population, advancement in technology, awareness of people about treatment options and favorable government policies. The Asia-Pacific market is projected to grow at double digit CAGR from 2022 to 2029, while the RoW region is projected to grow at high single digit CAGR from 2022 to 2029.
Major players in the Glucose monitoring market include Abbott Laboratories (U.S.), Dexcom (U.S.), Roche (Switzerland), LifeScan (U.S.), Medtronic, Inc. (Ireland), PHC Holding (Ascensia) (Japan), Sinocare (China), Arkray (Japan), Bio-Rad Laboratories (U.S.), and i-Sens, Inc., (South Korea), etc.
Table of Contents
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 THE GLOBAL RISE IN THE PREVALENCE OF DIABETES
3.3.1.2 INCREASING DEMAND FOR MINIMALLY OR NON-INVASIVE AND POINT-OF-CARE DEVICES.
3.3.1.3 INCREASING R & D INVESTMENTS
3.3.1.4 GROWING DIFFUSION OF SMART DEVICES AND DIGITAL PLATFORMS INCREASING COMPLIANCE AND MANAGEMENT OF DIABETES
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 HIGH COST ASSOCIATED WITH THE PRODUCTS
3.3.2.2 INADEQUATE REIMBURSEMENT
3.3.2.3 PRODUCT RECALLS
3.3.2.4 STRICT REGULATION OF GLUCOSE MONITORING DEVICES BY REGULATORY ORGANIZATIONS LIKE THE FDA AND OTHERS
3.3.2.5 PRIVACY CONCERN AND SAFETY ISSUES IN CONNECTED DEVICES
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 INDIA
3.4.5 JAPAN
3.5 REIMBURSEMENT SCENARIO
3.6 PATENT ANALYSIS
3.7 TECHNOLOGY ADVANCEMENTS
3.7.1 NON-INVASIVE GLUCOSE MONITORING TECHNOLOGIES
3.7.1.1 OPTICAL GLUCOSE MONITORING
3.7.1.2 BREATH GLUCOSE MONITORING
3.7.1.3 SWEAT GLUCOSE MONITORING
3.7.1.4 PIPELINE OF NON-INVASIVE GLUCOSE MONITORING DEVICES
3.8 FUNDING SCENARIO
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 BARGAINING POWER OF SUPPLIERS
3.9.4 BARGAINING POWER OF BUYERS
3.9.5 RIVALRY AMONG EXISTING COMPETITORS
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10.1 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.10.2 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.10.3 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.11 REGIONAL MARKET SHARE ANALYSIS
3.11.1 NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALSIS
3.11.2 EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.3 ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.4 ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.5 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.6 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.7 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.11.8 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12 UNITS SOLD
3.12.1 GLUCOSE TESTING STRIPS UNITS SOLD
3.12.2 NUMBER OF CGM SENSORS SOLD
3.13 MARKET PENETRATION ANALYSIS
3.13.1 GLOBAL SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.2 NORTH AMERICA SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.2.1 U.S. SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.2.2 REST OF N.A. SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3 EUROPE SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.1 GERMANY SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.2 FRANCE SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.3 ITALY SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.3.4 REST OF E.U. SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4 ASIA-PACIFIC SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.1 JAPAN SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.2 CHINA SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.3 INDIA SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.4.4 REST OF APAC SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5 REST OF THE WORLD SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5.1 BRAZIL SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5.2 MIDDLE EAST & OTHERS SMBG AND CGM MARKET PENETRATION ANALYSIS
3.13.5.3 REST OF LATAM SMBG AND CGM MARKET PENETRATION ANALYSIS
4 GLUCOSE MONITORING GLOBAL MARKET, BASED ON PRODUCTS
4.1 INTRODUCTION
4.2 INVASIVE GLUCOSE MONITORING
4.2.1 SELF GLUCOSE MONITORING
4.2.1.1 BLOOD GLUCOSE METER
4.2.1.2 BLOOD GLUCOSE TESTING STRIPS
4.2.1.3 LANCETS & OTHERS
4.2.2 CONTINUOUS GLUCOSE MONITORING
4.2.2.1 GLUCOSE SENSORS
4.2.2.2 TRANSMITTERS AND RECEIVERS
4.3 NON-INVASIVE GLUCOSE MONITORING
4.4 LAB BASED GLUCOSE MONITORING
5 GLUCOSE MONITORING GLOBAL MARKET, BASED ON SAMPLE SOURCE
5.1 INTRODUCTION
5.2 BLOOD-BASED GLUCOSE MONITORING
5.3 URINE BASED GLUCOSE MONITORING
5.4 OTHER SOURCES BASED GLUCOSE MONITORING
6 GLUCOSE MONITORING GLOBAL MARKET, BASED ON END-USERS
6.1 INTRODUCTION
6.2 HOSPITALS
6.3 HOME CARE
6.4 PRIVATE CLINICS
6.5 AMBULATORY SETTINGS
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 ITALY
7.3.3 FRANCE
7.3.4 REST OF EUROPE
7.4 ASIA - PACIFIC
7.4.1 JAPAN
7.4.2 CHINA
7.4.3 INDIA
7.4.4 REST OF ASIA-PACIFIC
7.5 REST OF THE WORLD
7.5.1 BRAZIL
7.5.2 MIDDLE EAST & OTHERS
7.5.3 REST OF LATIN AMERICA
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 AGREEMENTS, COLLABORATION & PARTNERSHIPS
8.3 APPROVALS
8.4 NEW PRODUCT LAUNCH
8.5 OTHER DEVELOPMENTS
9 MAJOR COMPANIES
9.1 ABBOTT LABORATORIES, INC.
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 ARKRAY, INC.
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 BIO-RAD LABORATORIES, INC.
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 DEXCOM, INC.
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 I-SENS, INC.
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 LIFESCAN
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 MEDTRONIC, PLC
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 PHC HOLDINGS (ASCENCIA DIABETES)
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 ROCHE HOLDINGS AG
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 SINOCARE INC.
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 2 SELF-MONITORING GLUCOSE TESTING STRIPS GLOBAL UNITS SOLD, BASED ON REGION, (2021-2029) (MN)
TABLE 3 CGM SENSORS GLOBAL UNITS SOLD, BASED ON REGION, (2021-2029) (MN)
TABLE 4 GLUCOSE MONITORING DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 5 INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 6 INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 7 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 8 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 9 BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 10 BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 11 LANCETS & OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 12 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 13 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 14 GLUCOSE SENSORS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 15 TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 16 NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 17 LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 18 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED SAMPLE SOURCE, (2021-2029) ($MN)
TABLE 19 BLOOD-BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 20 URINE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 21 OTHER SOURCES BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 22 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON END-USER, (2021-2029) ($MN)
TABLE 23 HOSPITAL GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 24 HOME CARE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 25 PRIVATE CLINICS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 26 AMBULATORY SETTING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 27 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 28 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 29 NORTH AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 30 NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 31 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 32 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 33 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 34 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 35 U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 36 REST OF N. A. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 37 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 38 EUROPE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 39 EUROPE SELF BLOOD GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 40 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 41 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 42 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 43 EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 44 GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 45 ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 46 FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 47 REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 48 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 49 ASIA-PACIFIC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 50 ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 51 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 52 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 53 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 54 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 55 JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 56 CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 57 INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 58 REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 59 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 60 ROW INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 61 ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 62 ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 63 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2021-2029) ($MN)
TABLE 64 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 65 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 66 BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 67 MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 68 REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 69 AGREEMENTS, COLLABORATION & PARTNERSHIPS (2021-2023)
TABLE 70 APPROVALS (2021-2023)
TABLE 71 NEW PRODUCT LAUNCH (2021-2023)
TABLE 72 OTHERS (2021-2023)
TABLE 73 ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 74 ABBOTT LABORATORIES, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
TABLE 75 ABBOTT LABORATORIES, INC: TOTAL REVENUE OF MEDICAL DEVICES, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
TABLE 76 ABBOTT LABORATORIES, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
TABLE 77 BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
TABLE 78 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2020-2022) ($MN)
TABLE 79 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) ($MN)
TABLE 80 DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2020-2022) ($MN)
TABLE 81 DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) ($MN)
TABLE 82 I-SENS, INC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
TABLE 83 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 84 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 85 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 86 PHC HOLDINGS: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 87 PHC HOLDINGS: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 88 PHC HOLDINGS: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 89 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 90 ROCHE HOLDINGS AG: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
TABLE 91 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE, BASED ON SUB-SEGMENT, (2020-2022) ($MN)
TABLE 92 ROCHE HOLDINGS AG: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
TABLE 93 SINOCARE, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
LIST OF FIGURES
FIGURE 1 GLUCOSE MONITORING GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION (2021-2029) ($MN) (%)
FIGURE 2 RESEARCH METHODOLOGY: GLUCOSE MONITORING GLOBAL MARKET
FIGURE 3 GLUCOSE MONITORING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 GLUCOSE MONITORING GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 GLUCOSE MONITORING GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION
FIGURE 7 PRODUCT MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 GLUCOSE MONITORING GLOBAL MARKET: PATENT FILING, BASED ON MAJOR PLAYERS (2017-2022)
FIGURE 10 GLUCOSE MONITORING MARKET: PORTER’S ANALYSIS
FIGURE 11 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 12 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 13 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 14 NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 15 EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 16 ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 17 ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 18 NORTH AMERICA CONTINOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 19 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 20 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 21 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022
FIGURE 22 SELF MONITORING GLUCOSE TEST STRIPS GLOBAL UNITS SOLD, BASED ON REGION AND COUNTRYWISE (2022) (MN)
FIGURE 23 CGM SENSORS GLOBAL UNITS SOLD, BASED ON REGION AND COUNTRYWISE (2022) (MN)
FIGURE 24 GLOBAL SELF-MONITORING OF BLOOD GLUCOSE (SMBG) MARKET PENETRATION, (2022)
FIGURE 25 GLOBAL CONTINUOUS GLUCOSE MONITORING (CGM) MARKET PENETRATION, (2022)
FIGURE 26 NORTH AMERICA SMBG MARKET PENETRATION, (2022)
FIGURE 27 NORTH AMERICA CGM MARKET PENETRATION, (2022)
FIGURE 28 U.S. SMBG MARKET PENETRATION, (2022)
FIGURE 29 U.S. CGM MARKET PENETRATION, (2022)
FIGURE 30 REST OF N.A. SMBG MARKET PENETRATION, (2022)
FIGURE 31 REST OF NA. CGM MARKET PENETRATION, (2022)
FIGURE 32 EUROPE SMBG MARKET PENETRATION, (2022)
FIGURE 33 EUROPE CGM MARKET PENETRATION, (2022)
FIGURE 34 GERMANY SMBG MARKET PENETRATION, (2022)
FIGURE 35 GERMANY CGM MARKET PENETRATION, (2022)
FIGURE 36 FRANCE SMBG MARKET PENETRATION, (2022)
FIGURE 37 FRANCE CGM MARKET PENETRATION, (2022)
FIGURE 38 ITALY SMBG MARKET PENETRATION, (2022)
FIGURE 39 ITALY CGM MARKET PENETRATION, (2022)
FIGURE 40 REST OF E.U. SMBG MARKET PENETRATION, (2022)
FIGURE 41 REST OF E.U. CGM MARKET PENETRATION, (2022)
FIGURE 42 ASIA-PACIFIC SMBG MARKET PENETRATION, (2022)
FIGURE 43 ASIA-PACIFIC CGM MARKET PENETRATION, (2022)
FIGURE 44 JAPAN SMBG MARKET PENETRATION, (2022)
FIGURE 45 JAPAN CGM MARKET PENETRATION, (2022)
FIGURE 46 CHINA SMBG MARKET PENETRATION, (2022)
FIGURE 47 CHINA CGM MARKET PENETRATION, (2022)
FIGURE 48 INDIA SMBG MARKET PENETRATION, (2022)
FIGURE 49 INDIA CGM MARKET PENETRATION, (2022)
FIGURE 50 REST OF APAC SMBG MARKET PENETRATION, (2022)
FIGURE 51 REST OF APAC CGM MARKET PENETRATION, (2022)
FIGURE 52 REST OF THE WORLD SMBG MARKET PENETRATION, (2022)
FIGURE 53 REST OF THE WORLD CGM MARKET PENETRATION, (2022)
FIGURE 54 BRAZIL SMBG MARKET PENETRATION, (2022)
FIGURE 55 BRAZIL CGM MARKET PENETRATION, (2022)
FIGURE 56 MIDDLE EAST & OTHERS SMBG MARKET PENETRATION, (2022)
FIGURE 57 MIDDLE EAST & OTHERS CGM MARKET PENETRATION, (2022)
FIGURE 58 REST OF LATAM SMBG MARKET PENETRATION, (2022)
FIGURE 59 REST OF LATAM CGM MARKET PENETRATION, (2022)
FIGURE 60 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 61 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 62 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 63 NON-INVASIVE GLUCOSE MONITORS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 64 LAB BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 65 GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 66 URINE BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 67 GLUCOSE MONITORING GLOBAL MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 68 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
FIGURE 69 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 70 NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 71 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 72 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 73 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 74 U.S. GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS SAMPLE SOURCE & END-USER (2022 VS 2029)($MN)
FIGURE 75 U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 76 REST OF NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCT, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
FIGURE 77 REST OF N. A. INVASIVEGLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 78 EUROPE AND INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 79 EUROPE SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 80 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 81 EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 82 EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 83 EUROPE GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 84 GERMANY GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE & END-USER (2022 VS 2029) ($MN)
FIGURE 85 GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 86 ITALY GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS SAMPLE SOURCE & END-USER (2022 VS 2029) ($MN)
FIGURE 87 ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 88 FRANCE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
FIGURE 89 FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 90 REST OF EUROPE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE, AND END-USER (2022 VS 2029) ($MN)
FIGURE 91 REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 92 ASIA-PACIFIC & INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 93 ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 94 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 95 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 96 ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 97 ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 98 JAPAN GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 99 JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 100 CHINA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 101 CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 102 INDIA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 103 INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 104 REST OF APAC GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 105 REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 106 ROW INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BASED ON PRODUCTS (2022) ($MN)
FIGURE 107 ROW SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 108 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
FIGURE 109 ROW GLUCOSE MONITORING MARKET SHARE, BASED ON SAMPLE SOURCE (2022 VS 2029) (%)
FIGURE 110 ROW GLUCOSE MONITORING MARKET SHARE, BASED ON END-USER (2022 VS 2029) (%)
FIGURE 111 ROW GLUCOSE MONITORING MARKET REVENUE, BASED ON COUNTRY (2022 VS 2029) ($MN)
FIGURE 112 BRAZIL GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 113 BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 114 MIDDLE EAST & OTHERS GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 115 MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 116 REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS, SAMPLE SOURCE AND END-USER (2022 VS 2029) ($MN)
FIGURE 117 REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
FIGURE 118 KEY GROWTH STRATEGIES (2021–2023)
FIGURE 119 SWOT: ABBOTT LABORATORIES
FIGURE 120 SWOT: ARKRAY, INC
FIGURE 121 SWOT: BIO-RAD LABORATORIES
FIGURE 122 SWOT: DEXCOM INC.
FIGURE 123 SWOT: I-SENS, INC.
FIGURE 124 SWOT: LIFESCAN
FIGURE 125 SWOT: MEDTRONIC, PLC
FIGURE 126 SWOT: PHC HOLDINGS (ASCENSIA DIABETES CARE)
FIGURE 127 SWOT: ROCHE HOLDINGS AG
FIGURE 128 SWOT: SINOCARE
LIST OF COMPANIES MENTIONED IN THE REPORT
1 77 Elektronika KFT
2 A&T Corporation
3 Abbott Laboratories
4 Abronn fze
5 ACON Laboratories, Inc
6 Adaltis S.r.l
7 Agamatrix, Inc.
8 Ailex Technology Group Co., Ltd
9 Alliance International Co. Ltd
10 Allmedicus Co., Ltd
11 Andesfit System Limited
12 Andon Health Co., Ltd.
13 Apex Biotechnology Corp.
14 Arkray, Inc.
15 Ascensia Diabetes Care Holdings AG
16 AYSET Medical Products
17 B. Braun Melsungen AG
18 Beato Curv
19 Becton Dickinson and Company
20 Beijing Dnurse Technology Co.,Ltd
21 Beijing Yicheng Bioelectronics Technology Co., Ltd.
22 Beurer Gmbh
23 BioCARE Corporation
24 Biochemical Systems International S.p.A.
25 Bioland Technology Ltd.
26 Bionime Corporation (GE)
27 Bioptik Ltd.
28 Bio-Rad Laboratories, Inc
29 BioTelemetry (Philips)
30 Biotest Medical Corporation
31 Bremed Limited
32 Cambridge Sensors Ltd (Microdot)
33 CEI Technology, Inc
34 ChungDo Pharm. Co., Ltd.
35 Cnoga Medical
36 Contec Medical Systems Co., Ltd.
37 Convergent Technologies GmbH & Co. KG
38 CTK Biotech, Inc.
39 Danaher Corporation (Hemocue)
40 Dario Health Corp.
41 Delbio, Inc.
42 Dexcom, Inc
43 Diabetomics, Inc
44 Diagnosis S.A.
45 Dialab GmbH
46 DiaMonTech AG
47 Dr. Morepen
48 Drive DeVilbiss Healthcare
49 EasyMax Diabetes Care
50 EKF Diagnostics
51 e-LinkCare Meditech Co., Ltd.
52 Eps Bio Technology Corp.
53 Eser Healthcare Digital Technology Co., Ltd.
54 Fia Biomed Gmbh
55 Fora Care, Inc
56 General Life Biotechnology Co., Ltd.
57 Genesis Health Technologies, Inc.
58 GlucoMe
59 GlucoRx
60 Glysens Incorporated
61 Goldsite Diagnostics Inc.
62 Guilin Urit Electronic Group Co.,Ltd
63 Haiden Technology Pvt Ltd
64 Hangzhou Sejoy Electronics & Instruments Co., Ltd.
65 Hannox International
66 HMD Biomedical Inc.
67 Hubdic Co Ltd
68 Ihealth Labs, Inc.
69 Ime-Dc Gmbh
70 In4 Technology Corporation
71 Informed Data Systems, Inc. (One Drop)
72 Infinovo Medical Co., Ltd.
73 Intuity Medical, Inc.
74 i-Sens
75 Ixensor Company Ltd.
76 Jiangsu Yuyue Medical Equipment & Supply Co., Ltd (Yuwell)
77 Keto-Mojo Europe B.V.
78 K-Jump Health Co., Ltd.
79 Lepu Medical Technology
80 Life Scan, Inc.
81 Lifotronic Technology Co., Ltd
82 Links Medical Products Inc.
83 Lobeck Medical AG
84 L-Tac MediCare Pte Ltd.
85 Medconn Diagnostics
86 Medisana, GmbH
87 Mediwise (V.S. International)
88 Medsource Ozone Biomedicals Pvt. Ltd.
89 Medtronic, PLC
90 Medtrum Technologies, Inc
91 Menarini Group (A. Menarini Diagnostics s.r.l)
92 Mericonn Technology Co., Ltd.
93 Meril Life Sciences Pvt. Ltd.
94 MHC Medical Products, LLC
95 Microlife AG
96 MicroTech Medical, Inc. (Aidex, Ltd)
97 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
98 National Diagnostic Products Pty Ltd (Betachek)
99 Nemaura Medical,Inc.
100 Nipro Corporation
101 Nova Biomedical
102 Noviosense BV
103 nu-beca & maxcellent Co.
104 Occuity
105 Ok Biotech Co., Ltd
106 Omron Healthcare
107 Osang HealthCare Co Ltd
108 Palmdoc, Ltd
109 Paramedical srl
110 Pharma Tech Solutions, Inc.
111 Philosys Co., Ltd.
112 Pkvitality
113 Prodigy Diabetes Care, LLC
114 Pulsatom Healthcare Pvt., Ltd.
115 Roche Diagnostics
116 Romed Holland (Van Oostveen Medical B.V.)
117 Sanofi Diabetes
118 SD Biosensor. Inc.
119 Sensa Core Medical Instrumentation Pvt. Ltd.
120 Senseonics, Inc.
121 Shanghai Umitai Medical Technology Co., Ltd
122 Sinocare Inc
123 Taidoc Technology Corporation
124 Terumo
125 Tianjin Empecs Medical Device Co., Ltd.
126 Trinity Biotech, PLC
127 Trividia Health, Inc.,
128 Tyson Bioresearch Inc
129 Visgeneer
130 VivaChek Biotech (Hangzhou) Co., Ltd
131 Volta S.r.l.
132 WaveForm Technologies, Inc.
133 Wellan Tech Co., Limited
134 Wockhardt Ltd
135 Wuhan J.H.Bio-Tech
136 Wuxi BioHermes Bio & Medical Technology Co. Ltd.
137 Ypsomed AG
Related Report
